Advertisement
  • Loading metrics

Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target

  • Nir Osherov,

    Affiliation Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  • Ronen Ben-Ami

    ronenba@tlvmc.gov.il

    Affiliations Infectious Disease Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, Department of Medicine, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target

  • Nir Osherov, 
  • Ronen Ben-Ami
PLOS
x

Correction

17 Aug 2016: Osherov N, Ben-Ami R (2016) Correction: Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target. PLOS Pathogens 12(8): e1005838. https://doi.org/10.1371/journal.ppat.1005838 View correction

Angiogenesis in Health and Disease

The blood vascular system is essential to the development and maintenance of tissues of multicellular eukaryotes. Its roles include internal transport and delivery of oxygen and nutrients and immune surveillance and trafficking of cells and molecules of the innate immune system to sites of tissue damage. Formation of blood vessels occurs by two principal modes: assembly of endothelial progenitor cells into vascular networks (vasculogenesis), which takes place predominantly in embryonic life, and the expansion of existing vascular systems by sprouting of new blood vessels from existing ones (angiogenesis) [1]. Angiogenesis is a sequential process guided by angiogenic cues, notably, hypoxia inducible factor (HIF)-1, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), angiopoietin-2, and chemokines released by hypoxic, inflammatory, or neoplastic cells [1].

Whereas physiological angiogenesis is essential for normal tissue growth, remodeling, and regeneration, dysregulated angiogenesis plays a pivotal role in disease states, including cancer, inflammatory diseases, atherosclerosis, and diabetic retinopathy [2]. Importantly, cancer cells can exploit angiogenesis to support their own proliferation and metastatic dissemination. This so-called tumor angiogenesis has been the focus of intense research, leading to the discovery of a novel class of antineoplastic drugs [3]. During infection, angiogenesis is induced when microbial motifs are detected in concert with damage-associated molecular patterns. Specifically, bacterial ligands such as LPS and unmethylated CpG activate mammalian Toll-like receptors (TLRs) 2, 4, 7, and 9, while adenosine, a danger signal that accumulates rapidly in ischemic or damaged tissues, synergizes with TLRs to induce the synthesis and release of VEGF and recruitment of endothelial progenitor cells [4]. The ensuing inflammatory angiogenic response facilitates the migration of leukocytes to infected tissue and wound repair. Moreover, an emerging concept links angiogenesis to innate immunity, implying that an adequate angiogenic response is required for control and clearance of invading pathogens [57]. Intriguingly, some microbial pathogens manipulate the host angiogenic response, either suppressing it to enhance their persistence in tissues or hijacking angiogenesis for their own ends. Deciphering such interactions may uncover new therapeutic targets for some of the most tenacious infectious diseases. In this mini-review, we highlight examples where modulation of host angiogenesis has been shown to play an important role in microbial pathogenesis.

Regional Events at Infection Sites Control Microbial Sequestration and Killing

The evolution of a circulatory system enables a systemic immune response but opens the way for rapid dissemination of pathogens within the host. Rapid microbial dissemination is controlled via early local events that wall off invading pathogens [8]. Microbial sequestration addresses contrasting needs; it must enable migration of immune cells and antimicrobial molecules into infected tissue while preventing pathogens from gaining access to the circulatory system. Failure to achieve these goals results in microbial persistence or dissemination, respectively. The early events that occur within hours of microbial invasion include triggering of the complement cascade and platelet aggregation followed by the expression of adhesion molecules (endothelial-leukocyte adhesion molecule [ELAM]-1, intercellular adhesion molecule [ICAM]-1, and vascular cell adhesion molecule [VCAM]-1) on activated endothelial cells, facilitating the influx of immune cells to infected tissue [9].

The microenvironmental conditions at the site of infection are characterized by low oxygen pressure and high concentrations of lactate and reductive metabolites. This is especially true if the local vasculature is directly disrupted by infection. The heterodimeric transcription factor HIF-1 is the pivotal regulator of angiogenesis and myeloid cell function under hypoxic conditions. HIF-1α levels are dynamically controlled by oxygen-dependent prolyl hydroxylase domain (PHD) proteins that regulate HIF stability [10]. Moreover, HIF-1 and NF-kB signaling are strongly interdependent, with intact NF-kB signaling shown to be required for hypoxic HIF-1 induction [11,12]. HIF-1 activation is observed in infections with bacteria, viruses, fungi, and protozoa [13]. Interestingly, hypoxia-independent activation of HIF-1α is induced by iron deprivation, suggesting that bacterial siderophores may also trigger this pathway [14]. Myeloid aggregation, motility, invasion, and bacterial killing are critically dependent on HIF-1α, which allows myeloid cells to function under conditions of low oxygen pressure by switching to glycolytic metabolism [15]. In sum, HIF-1 activation of VEGF signaling and angiogenesis likely act in concert with myeloid cell activation and trafficking to keep tissue-invasive pathogens in check.

Some Pathogens Enhance Host Angiogenesis to Support Infection

Infection-associated angiogenesis has been described in diverse infections caused by bacteria, viruses, protozoa, and fungi (Table 1). Conceptually, infectious angiogenesis may be classified as either direct induction of host angiogenesis by pathogen-derived molecules or angiogenesis driven by a nonspecific host inflammatory response. Both Bartonella henselae and Kaposi sarcoma-associated herpesvirus (KSHV) induce rampant angiogenesis, resulting in severe illness in persons with deficient cellular immunity, such as patients with AIDS. The B. henselae adhesin A (BadA) and type IV secretion system VirB/D4 mediate bacterial endothelial cell adherence and uptake followed by activation of a proangiogenic phenotype, thereby expanding the host cell habitat of this pathogen [16]. KSHV expresses several factors that either directly activate the formation of blood vessels (viral interleukin 6 [vIL-6], vCCL-1, and vCCL-II) or indirectly activate cell pathways, leading to angiogenesis (vGPCR, vFLIP, K1, K15, KSHV miRNAs) [17]. Virus-driven angiogenesis enables propagation of KSHV by recruiting uninfected endothelial lineage and hematopoietic cells for further infection and reactivation of KSHV in latently infected cells [18].

thumbnail
Table 1. Notable pathogens associated with modulation of host angiogenesis.

https://doi.org/10.1371/journal.ppat.1005479.t001

M. tuberculosis, the causative agent of tuberculosis, has not been found to produce bacterial angiogenic factors, yet its ability to survive and persist in the host is intimately related to pathological angiogenesis [6,19]. M. tuberculosis elicits the formation of dense cellular aggregates (granulomas) that wall off the pathogen. The presence of viable mycobacteria within macrophages in granulomas triggers VEGF-dependent tumor–like angiogenesis associated with dysfunctional (leaky) blood vessels. Dysregulated angiogenesis further limits perfusion of the granuloma core, exacerbating hypoxia and causing caseating necrosis, a hallmark of this infection (Fig 1). Pathological angiogenesis may be an important cause of inadequate delivery of antibiotic drugs and immune cells to the center of the granuloma, necessitating multidrug combinations and protracted treatment courses to eradicate the disease [6,19].

thumbnail
Fig 1. Modulation of angiogenesis in tuberculosis and invasive aspergillosis.

A. Vascular endothelial growth factor (VEGF)-mediated, host-induced pathological angiogenesis in M. tuberculosis granulomas restricts perfusion of the granuloma core and attenuates antituberculosis drug efficacy of rifampicin (RIF). B. Treatment with the angiogenesis-inhibiting drug bevacizumab (Beva) reverses pathological angiogenesis, enhances perfusion of the granuloma core, and synergizes with rifampicin. C. A. fumigatus hyphae invade pulmonary arterioles and induce intravascular thrombosis. The compensatory angiogenic response is down-regulated by gliotoxin (GT) and other fungal secondary metabolites, further limiting perfusion of infected tissue with the antifungal drug amphotericin B (AmB). D. Treatment with proangiogenic growth factors VEGF and fibroblast growth factor (FGF) counteracts the action of gliotoxin and enhances the influx of polymorphonuclear leukocytes and antifungal drugs to the site of infection.

https://doi.org/10.1371/journal.ppat.1005479.g001

Attenuation of Host Angiogenesis Creates Sequestered Niches Where Pathogens Persist

Inhibition of angiogenesis during infection interferes with tissue healing and facilitates a hypoxic and/or necrotic milieu that compromises immune function and favors pathogen persistence (Table 1). A. fumigatus produces life-threatening pulmonary infection in immunocompromised individuals, principally patients with hematological malignancies and recipients of hematopoietic stem cell transplantation [20]. In the setting of profound neutropenia, airborne spores (conidia) are inhaled into pulmonary alveoli, where they germinate and form tissue-invasive filaments (hyphae) that bore through the alveolar–capillary barrier and invade pulmonary arterioles [20]. Angioinvasion is associated with endothelial injury, tissue factor expression, triggering of the coagulation cascade, and platelet activation [21]. Collectively, these processes impair vascular perfusion of Aspergillus-infected lung tissue, producing a necrotic core where fungal hyphae proliferate abundantly, surrounded by a peripheral zone of alveolar hemorrhage (Fig 1) [22]. The importance of adaptation to hypoxia for A. fumigatus pathogenesis is underscored by work showing that deletion of the SrbA gene, which is essential for survival in hypoxic environments, renders A. fumigatus nonvirulent [23]. Invasive pulmonary aspergillosis is associated with a rapid increase in tumor necrosis factor (TNF)α transcription in mouse lungs but down-regulation of angiogenesis mediators that are normally induced by this cytokine: VEGF, FGF, and their receptors [24]. Uncoupling of inflammatory mediators and angiogenesis is further evident in reduced microvascular density around necrotic pulmonary lesions [7,25]. Inhibition of angiogenesis is mediated by A. fumigatus secondary metabolites, chiefly gliotoxin, under the transcriptional control of LaeA [24]. Attenuated angiogenesis likely perpetuates tissue hypoxia and limits trafficking of immune cells and antifungal drugs into the site of Aspergillus infection [5,20]. Thus, the vasculopathy of invasive aspergillosis plays a pathogenic role by restricting innate immune cell traffic to the site of infection and optimizing local growth conditions for the fungus.

Modulation of Host Angiogenesis as a Therapeutic Target in Infections

The concept of angiogenesis modulation as a novel microbial virulence factor suggests the potential for attenuating pathogenicity using vascular-active molecules. Cancer research has produced numerous monoclonal antibodies and small molecules that target VEGF and its receptor (VEGFR) [3,26,27]. Originally thought to deprive tumors of their vascular supply, these agents are now believed to increase perfusion and alleviate hypoxia by normalizing tumor vasculature [27]. Similarly, angiogenesis modulators have little if any direct antimicrobial activity but act synergistically with conventional antimicrobials by enhancing drug delivery to the anatomical site of infection.

This idea has been explored in a rabbit model of M. tuberculosis infection and a zebrafish model of Mycobacterium marinum infection [6,19]. Inhibition of angiogenesis using bevacizumab, an anti-VEGF-A monoclonal antibody [6], and VEGFR tyrosine kinase inhibitors SU5416 and pazopanib [19] prevented the formation of abnormal ectopic blood vessels around mycobacterial granulomas, improved granuloma perfusion, and decreased necrotic tissue volume, bacterial burden, and dissemination without directly affecting mycobacterial growth in vitro (Fig 1) [6,19]. Moreover, pazopanib treatment alone significantly increased survival in the M. marinum zebrafish model, and SU5416 potentiated the activity of the first-line antituberculosis drug rifampicin [19].

In contrast, the vasculopathy of invasive aspergillosis is reversed following repletion of proangiogenic factors [7]. Treatment with VEGF and FGF alone significantly increased survival in a neutropenic mouse model of invasive pulmonary aspergillosis, and both growth factors acted synergistically with the antifungal drug amphotericin B to enhance survival and decrease pulmonary fungal burden (Fig 1) [7]. FGF enhanced the generation of CD31-positive vessels and was associated with neutrophil infiltrates around A. fumigatus infection sites. Interestingly, FGF had a more potent effect on mouse survival and fungal burden than did VEGF, a fact consistent with the association of VEGF with immature and hyperpermeable blood vessels [7].

These preliminary findings should be viewed within the context of the grand challenges to healthcare presented by M. tuberculosis and A. fumigatus [28,29]. M. tuberculosis infects one-third of the world’s population and is the second greatest cause of infectious mortality worldwide [29]. Currently, treatment involves complex multidrug regimens lasting months, which many patients do not tolerate. Moreover, extensive resistance to antituberculosis drugs has emerged in some parts of the world [29]. Invasive aspergillosis is lethal in about one-third of patients [30], and resistance to voriconazole, the foremost drug used to treat this infection, is spreading across Europe and Asia [31]. Vascular targeted therapies may herald the prospect of more effective antimicrobial drug delivery, allowing shorter, simpler treatment regimens and more efficient pathogen clearance.

References

  1. 1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473: 298–307. pmid:21593862
  2. 2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438: 932–936. pmid:16355210
  3. 3. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3: 24–40. pmid:16407877
  4. 4. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol 2003;163: 711–721. pmid:12875990
  5. 5. Ben-Ami R. Angiogenesis at the mold-host interface: a potential key to understanding and treating invasive aspergillosis. Future Microbiol 2013;8: 1453–1462. pmid:24199803
  6. 6. Datta M, Via LE, Kamoun WS, Liu C, Chen W, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A 2015;112: 1827–1832. pmid:25624495
  7. 7. Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis 2013;207: 1066–1074. pmid:23303813
  8. 8. Saadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J 2002;16: 849–856. pmid:12039867
  9. 9. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101: 3765–3777. pmid:12543869
  10. 10. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294: 1337–1340. pmid:11598268
  11. 11. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, et al. An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 2011;186: 1091–1096. pmid:21149600
  12. 12. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008;586: 4055–4059. pmid:18599532
  13. 13. Werth N, Beerlage C, Rosenberger C, Yazdi AS, Edelmann M, et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS ONE 2010;5: e11576. pmid:20644645
  14. 14. Hartmann H, Eltzschig HK, Wurz H, Hantke K, Rakin A, et al. Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores. Gastroenterology 2008;134: 756–767. pmid:18325389
  15. 15. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112: 645–657. pmid:12628185
  16. 16. Siamer S, Dehio C. New insights into the role of Bartonella effector proteins in pathogenesis. Curr Opin Microbiol 2015;23: 80–85. pmid:25461577
  17. 17. Gramolelli S, Schulz TF. The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol 2015;235: 368–380. pmid:25212381
  18. 18. Cavallin LE, Goldschmidt-Clermont P, Mesri EA. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS. PLoS Pathog 2014;10: e1004154. pmid:25010730
  19. 19. Oehlers SH, Cronan MR, Scott NR, Thomas MI, Okuda KS, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature 2015;517: 612–615. pmid:25470057
  20. 20. Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 2010;150: 406–417. pmid:20618330
  21. 21. Kamai Y, Chiang LY, Lopes Bezerra LM, Doedt T, Lossinsky AS, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006;44 Suppl 1: S115–117. pmid:17050430
  22. 22. Shibuya K, Ando T, Hasegawa C, Wakayama M, Hamatani S, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother 2004;10: 138–145. pmid:15290452
  23. 23. Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog 2008;4: e1000200. pmid:18989462
  24. 24. Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009;114: 5393–5399. pmid:19843884
  25. 25. Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis 2013.
  26. 26. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407: 249–257. pmid:11001068
  27. 27. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014;26: 605–622. pmid:25517747
  28. 28. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science 2012;336: 647. pmid:22582229
  29. 29. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368: 745–755. pmid:23425167
  30. 30. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347: 408–415. pmid:12167683
  31. 31. van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, et al. Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus. Emerg Infect Dis 2015;21: 1041–1044. pmid:25988348
  32. 32. O'Rourke F, Mandle T, Urbich C, Dimmeler S, Michaelis UR, et al. Reprogramming of myeloid angiogenic cells by Bartonella henselae leads to microenvironmental regulation of pathological angiogenesis. Cell Microbiol 2015;17(10):1447–63. pmid:25857345
  33. 33. Dehio C. Infection-associated type IV secretion systems of Bartonella and their diverse roles in host cell interaction. Cell Microbiol 2008;10: 1591–1598. pmid:18489724
  34. 34. Ashman RB, Papadimitriou JM. Endothelial cell proliferation associated with lesions of murine systemic candidiasis. Infect Immun 1994;62: 5151–5153. pmid:7523305
  35. 35. Barker KS, Park H, Phan QT, Xu L, Homayouni R, et al. Transcriptome profile of the vascular endothelial cell response to Candida albicans. J Infect Dis 2008;198: 193–202. pmid:18500935
  36. 36. MacManiman JD, Meuser A, Botto S, Smith PP, Liu F, et al. Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesis. MBio 2014;5: e02035. pmid:25352622
  37. 37. Hassan M, Selimovic D, El-Khattouti A, Soell M, Ghozlan H, et al. Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies. World J Gastroenterol 2014;20: 15467–15475. pmid:25400432
  38. 38. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, et al. Angiogenesis and antiangiogenic agents in cervical cancer. Onco Targets Ther 2014;7: 2237–2248. pmid:25506227
  39. 39. Dennis RD, Schubert U, Bauer C. Angiogenesis and parasitic helminth-associated neovascularization. Parasitology 2011;138: 426–439. pmid:21232174
  40. 40. Kanse SM, Liang O, Schubert U, Haas H, Preissner KT, et al. Characterisation and partial purification of Schistosoma mansoni egg-derived pro-angiogenic factor. Molecular and Biochemical Parasitology 2005;144: 76–85. pmid:16169609
  41. 41. Loeffler DA, Lundy SK, Singh KP, Gerard HC, Hudson AP, et al. Soluble egg antigens from Schistosoma mansoni induce angiogenesis-related processes by up-regulating vascular endothelial growth factor in human endothelial cells. J Infect Dis 2002;185: 1650–1656. pmid:12023772
  42. 42. Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, et al. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res 2007;67: 9980–9985. pmid:17942931
  43. 43. Vasil ML, Stonehouse MJ, Vasil AI, Wadsworth SJ, Goldfine H, et al. A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells. PLoS Pathog 2009;5: e1000420. pmid:19424430